New Studies Say SmartPill® Delivers Window into Gastrointestinal Motility Disorders

Two new studies on Given Imaging’s SmartPill® device provide an insight into the usefulness of this technology in understanding gastrointestinal motility. The papers have been presented as posters at the American College of Gastroenterology’s 2013 Annual Scientific Meeting (ACG) taking place this week October 11-16, 2013 in San Diego.


Capsule Endoscope company Given Imaging Ltd, says results from these studies provide new information about gastroparesis, constipation and small intestinal bacterial overgrowth when using its SmartPill product. The studies were presented by researchers from the Cleveland Clinic and Texas Tech University Health Sciences Center.

First cleared for marketing as far back as 2006, the SmartPill motility monitoring system offers a unique way to assess motility by collecting and analyzing data from within the entire GI tract via a test that can be performed in the clinic or physician’s office. The test is ambulatory, allowing the patient to go about their normal routine throughout the test. As the SmartPill capsule passes through the GI tract, it transmits data to a recorder worn by the patient. Once the single-use capsule has passed from the body, study data are downloaded from the recorder to a computer. The physician then uses MotiliGI® software to display and analyze the data, providing test results in both graphical and report formats. Results are used for the evaluation of gastroparesis and chronic constipation.

The first paper was entitled: “Clinical Utility and Diagnostic Yield of 165 Wireless Capsule Studies at a Tertiary Referral Center,” poster 1684: presented by Zubin Arora, M.D., and colleagues from the Cleveland Clinic, is a retrospective study of 165 patients with suspected motility disorders who underwent SmartPill studies. You can find more detailed results in the press release, here, but in essence the device provided a useful insight into transit time in the various bowel sections, including abnormal findings in 785 of patients.

The second paper was entitled: “Does Small Intestinal Bacterial Overgrowth Delay Small Bowel Transit Time?,” poster 767: presented by Irene Sarosiek, M.D., and colleagues from Texas Tech University.  Investigators used SmartPill to explore the theory that symptoms of chronic idiopathic constipation may be related to alterations and abnormal colonization within the gut microbiata resulting in small intestinal bacterial overgrowth. The study found that small bowel transit time was 20% slower in patients with small intestinal bacterial overgrowth. After two weeks of treating the patients’ constipation with lubiprostone, 37% no longer had small intestinal bacterial overgrowth and their small bowel transit time was reduced by 21%.

Physician comments

“SmartPill provides clinicians with a powerful tool that helps us measure GI tract transit in patients who we cannot otherwise evaluate,” said Zubin Arora M.D., Cleveland Clinic. “In our study, SmartPill revealed that many patients with symptoms suggestive of gastroparesis or constipation actually have more generalized gut dysmotility which definitely has implications for how we manage these patients therapeutically.”

Source: Given Imaging Ltd., Globe Newswire